Literature DB >> 16003317

Factors predicting failure to identify a sentinel lymph node in breast cancer.

Anees B Chagpar1, Robert C Martin, Charles R Scoggins, David J Carlson, Alison L Laidley, Souzan E El-Eid, Terre Q McGlothin, Robert D Noyes, Phillip B Ley, Todd M Tuttle, Kelly M McMasters.   

Abstract

BACKGROUND: Although sentinel lymph node (SLN) biopsy is widely accepted as a minimally invasive method of nodal staging, failure to identify an SLN mandates a level I/II axillary node dissection. The purpose of this study was to elucidate factors that independently predict failure to identify an SLN.
METHODS: Using a large multicenter prospective study of SLN biopsy for patients with invasive breast cancer, we performed univariate and multivariate regression analyses to determine clinicopathologic factors predictive of failure to identify an SLN.
RESULTS: Of the total 4131 patients in the study, an SLN was not identified in 249 (6.0%). Tumor location (P = .409), biopsy type (P = .079), surgery type (P = .380), and histologic subtype (P = .999) were not significant predictors of failure to identify an SLN. On multivariate analysis, age greater than 60 years (OR = 1.469; 95% CI, 1.116-1.934, P = .006), nonpalpable tumors (OR = 0.639; 95% CI, 0.479-0.852, P = .002), injection technique with blue dye alone (OR = 0.389, 95% CI, 0.259-5.86, P < .001), and surgical experience of less than 10 SLN biopsy cases (OR = 1.886; 1.428-2.492, P < .001) were significant independent predictors of failure to identify an SLN. Optimal SLN biopsy technique using an intradermal and/or subareolar injection of radioactive colloid and blue dye can improve SLN identification rates regardless of patient and tumor characteristics.
CONCLUSIONS: Patient age and tumor palpability significantly affect the ability to identify an SLN in patients with breast cancer. Optimal injection technique can significantly improve sentinel node identification rate regardless of these factors.

Entities:  

Mesh:

Year:  2005        PMID: 16003317     DOI: 10.1016/j.surg.2005.03.003

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  21 in total

1.  The influence of wire localisation for non-palpable breast lesions on visualisation of the sentinel node.

Authors:  J E Jansen; J Bekker; M J de Haas; F A van der Weel; G H M Verberne; L M Budel; L G B A Quekel; J M H de Klerk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-28       Impact factor: 9.236

2.  Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).

Authors:  Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Teresa S Flippo-Morton; Henry M Kuerer; Monet Bowling; Kelly K Hunt
Journal:  Ann Surg       Date:  2015-03       Impact factor: 12.969

Review 3.  Sentinel lymph node mapping in endometrial cancer: comparison of fluorescence dye with traditional radiocolloid and blue.

Authors:  Andrea Papadia; Maria Luisa Gasparri; Alessandro Buda; Michael D Mueller
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-21       Impact factor: 4.553

4.  Sentinel Node Biopsy in Special Histologic Types of Invasive Breast Cancer.

Authors:  Montserrat Solà; Mireia Recaj; Eva Castellà; Pere Puig; Josep Maria Gubern; Juan Francisco Julian; Manel Fraile
Journal:  J Breast Health       Date:  2016-04-01

5.  Long-term follow-up results of fluorescence and blue dye guided sentinel lymph node biopsy in early breast cancer.

Authors:  Chaobin Wang; Fuzhong Tong; Yingming Cao; Peng Liu; Bo Zhou; Hongjun Liu; Lin Cheng; Miao Liu; Jiajia Guo; Fei Xie; Houpu Yang; Siyuan Wang; Yuan Peng; Shu Wang
Journal:  Breast Cancer Res Treat       Date:  2021-03-24       Impact factor: 4.872

6.  Re-evaluation of axillary skip metastases in the era of sentinel lymph node biopsy in breast cancer.

Authors:  Mehmet Keskek; Sener Balas; Aytac Gokoz; Iskender Sayek
Journal:  Surg Today       Date:  2006-12-25       Impact factor: 2.549

7.  Pre-operative sentinel lymph node localization in breast cancer with superparamagnetic iron oxide MRI: the SentiMAG Multicentre Trial imaging subprotocol.

Authors:  Joost J Pouw; Maarten R Grootendorst; Roland Bezooijen; Caroline A H Klazen; Wieger I De Bruin; Joost M Klaase; Margaret A Hall-Craggs; Michael Douek; Bennie Ten Haken
Journal:  Br J Radiol       Date:  2015-10-22       Impact factor: 3.039

8.  Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial.

Authors:  Marieke E Straver; Philip Meijnen; Geertjan van Tienhoven; Cornelis J H van de Velde; Robert E Mansel; Jan Bogaerts; Nicole Duez; Luigi Cataliotti; Jean H G Klinkenbijl; Helen A Westenberg; Huub van der Mijle; Marko Snoj; Coen Hurkmans; Emiel J T Rutgers
Journal:  Ann Surg Oncol       Date:  2010-03-19       Impact factor: 5.344

9.  Sentinel lymph node accumulation of Lymphoseek and Tc-99m-sulfur colloid using a "2-day" protocol.

Authors:  Anne M Wallace; Carl K Hoh; Karl K Limmer; Denise D Darrah; Gery Schulteis; David R Vera
Journal:  Nucl Med Biol       Date:  2009-08       Impact factor: 2.408

10.  Comparison of a 1-day and a 2-day protocol for lymphatic mapping and sentinel lymph node biopsy in patients with nonpalpable breast cancer.

Authors:  S van Esser; M Hobbelink; J W Van Isselt; W P Th M Mali; I H M Borel Rinkes; R van Hillegersberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-25       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.